

Quarterly Activities Report and Appendix 4C

Bio-Gene Technology Limited (ASX:BGT, “Bio-Gene” or “the Company”), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides this update on activities for the quarter ended 30 June 2025 (Q5 FY25).

Bio-Gene is focused on advancing the development and regulatory approval of Flavocide® and Qcide®, Bio-Gene’s two novel insecticidal active ingredients derived from nature. These compounds have novel modes of action and are being developed by Bio-Gene to address critical gaps in global pest control markets, including crop protection, public health and consumer applications, where resistance to conventional chemistries is rising and regulatory pressure is increasing.

Commenting on the focus during Q4 FY25, Managing Director & CEO Tim Grogan said:

“We are very grateful to our existing and new shareholders for supporting Bio-Gene by participating in our recent capital raise. The capital raised provides significant assistance to support the development of these very important and unique products for the sector.”

“Through the quarter, we continued to execute on our strategic priorities. This quarter, we have undertaken significant preparations for the commencement of key safety studies to support the development of Flavocide. We have also continued to leverage grant funding to drive progress while maintaining capital efficiency. The programs under the US Department of Defense’s Deployed Warfighter Protection initiative, which support the development of Flavocide® and Qcide®-based products for military and civilian use, highlight the growing international validation of our technology.

“With multiple partnerships already in place and a clearly defined regulatory and commercial pathway, Bio-Gene is well-positioned to undertake key studies required to support our application for registration of Flavocide.”

\$2.1 million in Placement plus Share Purchase Plan for Eligible Shareholders

During the quarter, the Company successfully completed a capital raising initiative, generating total gross proceeds of approximately \$2.45 million. The funding was secured through a two-tranche placement to sophisticated and professional investors, alongside a Share Purchase Plan (SPP) offered to eligible shareholders.

The placement raised approximately \$2.1 million at an issue price of 2.3 cents per share. Tranche 1 of the placement raising approximately \$1.16 million, was conducted under Bio-Gene’s existing placement capacity. Tranche 2, which raised a further \$0.9 million, was subject to shareholder approval. This approval was obtained at an Extraordinary General Meeting held on 14 July 2025. In addition to receiving shares in the Company, participants in the placement received two free-attaching unlisted options for every two shares issued – comprised of an option exercisable at A\$0.034 expiring in May 2028, and another exercisable at A\$0.046 expiring in May 2030.

The SPP, which closed on 28 May 2025, raised a further \$338,500 from eligible shareholders. Shares were issued at the same price of 2.3 cents per share, with participants also entitled to receive free-attaching options on the same terms as those offered in the placement.

The capital raised will support several key initiatives, including funding the regulatory-enabling safety studies required for the approval of Flavocide in Australia, progressing the scale-up of Qcide production and advancing product development efforts in support of Bio-Gene's commercial partnerships. The funds also supported strategic R&D projects, operational execution, and general working capital.

Qcide production enhancement and scale-up

During the quarter, Bio-Gene continued programs aimed at enhancing and expanding Qcide production to meet future demand for quality oil, including:

- Replacement of some areas of the plantation in North Queensland with new plantings and preparations made for expansion of the current plantation area.
- Further characterisation of the seed production area established from an older section of the plantation was undertaken as part of selection for grafting and seed production.
- Another Qcide oil harvest was undertaken in early July that incorporated experimentation in collaboration with James Cook University that demonstrated the value of pre-conditioning biomass prior to distillation as a means to further increase Qcide oil yields and reduce production costs as part of larger-scale deployment.

Outlook

Bio-Gene is poised to commence the next stage of critical regulatory-enabling safety studies required to support the first application for regulatory approval for Flavocide. Over the coming quarters, Bio-Gene will be generating the core data required to demonstrate the safety of Flavocide for inclusion in our regulatory dossier and we look forward to providing updates on this progress.

In addition, our engagement with a wide range of international commercial and collaborative development partners is continuing to support the market relevance for both Flavocide and Qcide, along with the increasing interest in biologically derived new products with a novel mode of action.

Approved for release by the Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright, NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited in Australia.

Appendix 4C

Quarterly cash flow report for entities
subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN

32 071 735 950

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date \$A'000
1. Cash flows from operating activities		
1.1 Receipts from Tax Incentive	-	536
1.2 Payments for		
(a) commercialisation expenses	(134)	(608)
(b) research and development	(385)	(1,380)
(c) intellectual property	(31)	(246)
(d) professional services	(54)	(74)
(e) directors' expenses	(47)	(189)
(f) administration and corporate costs (see note 6)	(369)	(622)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	3	40
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,016)	(2,543)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,496	1,496
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(76)	(76)
3.5	Proceeds from borrowings	51	51
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (share proceeds received in advance)		
3.10	Net cash from / (used in) financing activities	1,471	1,471

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
		683	2,210
4.1	Cash and cash equivalents at beginning of period		
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,016)	(2,543)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,471	1,471
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,138	1,138

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	79	133
5.2	Call deposits	559	605
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	500	600
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,138	1,338

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate number of payments to related parties and their associates included in item 1	189
6.2	Aggregate number of payments to related parties and their associates included in item 2	N/A

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Note 6.1: Director's fees paid to Directors or their related entities plus remuneration paid to Executive Directors.

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	N/A	N/A
7.2	Credit standby arrangements	N/A	N/A
7.3	Other (please specify)	N/A	N/A
7.4	Total financing facilities	N/A	N/A
7.5	Unused financing facilities available at quarter end	N/A	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,016)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,138
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	122
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.11
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	No, net operating cash flow is expected to be better next quarter as the Company has completed a share placement on 21 July 2025 raising \$965,121 for working capital purposes.	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	Since close of quarter, the entity had completed share placement on 21 July 2025 raising \$965,121 for working capital purposes.	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	Yes, the entity has the placement capacity to raise capital to meet its business objectives if required.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2025

Authorised by: The Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year-to-date basis. Movements disclosed for the current quarter have been correctly calculated.